Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01

Group 1 - Karolinska Development's portfolio company AnaCardio has completed enrollment in the phase 2a part of its clinical study GOAL-HF1, which evaluates the drug candidate AC01 in patients with heart failure and reduced ejection fraction, with results expected by the end of the year [1][4] - The phase 2a study includes 26 patients and aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics after 28 days of treatment, conducted at 13 specialized heart failure centers across Sweden, the Netherlands, Italy, and the UK [3] - Karolinska Development holds a 10 percent ownership stake in AnaCardio, indicating a vested interest in the success of the clinical study and the advancement of the drug candidate [4] Group 2 - AnaCardio AB is a privately held Swedish biopharmaceutical company focused on developing novel drugs for heart failure, with its lead asset AC01 currently in a clinical phase 1b/2a study [2] - Karolinska Development is a Nordic life sciences investment company that identifies and invests in breakthrough medical innovations, aiming to create and grow companies that develop these innovations into commercial products [5][6] - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by a team of experienced investment professionals and a strong global network [7]